サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1442870

がん支持療法薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Cancer Supportive Care Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
がん支持療法薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年
出版日: 2024年01月30日
発行: Transparency Market Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん支持療法薬市場 - レポートの範囲

世界のがん支持療法薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標に関する貴重な洞察を得る機会を研究しています。このレポートは、世界のがん支持療法薬の収益を提供します。 2023年を基準年、2031年を予測年として考慮した、2017年から2031年の期間のケア医薬品市場。このレポートは、2023年から2031年までの世界のがん支持療法薬市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、がん支持療法薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界のがん支持療法薬市場の競合情勢を詳しく掘り下げています。世界のがん支持療法薬市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のがん支持療法薬市場の企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017年～2031年
  • ポーターのファイブフォース分析

第5章 重要な洞察

  • 主要な薬物クラス/ブランド分析
  • 市場分野で活動するトップ 3プレーヤー
  • 病気の有病率と発生率
  • 新型コロナウイルスの影響分析

第6章 世界市場の分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 薬剤クラス別の市場金額予測、2017年～2031年
    • G-CSF（顆粒球コロニー刺激因子）
    • ESA（赤血球生成刺激剤）
    • 制吐薬
    • ビスホスホネート
    • オピオイド
    • NSAID（非ステロイド性抗炎症薬）
    • その他（話題など）
  • 薬剤クラス別の市場の魅力

第7章 世界市場の分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 適応症別の市場金額予測、2017年～2031年
    • 肺がん
    • 乳がん
    • 前立腺がん
    • 肝臓がん
    • 膀胱がん
    • 白血病
    • その他（卵巣がん、黒色腫など）
  • 適応症別の市場の魅力度

第8章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 流通チャネル別の市場金額予測、2017年～2031年
    • 病院薬局
    • 小売薬局
    • その他（調剤薬局等）
  • 流通チャネル別の市場魅力度

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 地域別の市場金額予測
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 国・地域別の市場魅力度

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東・アフリカ市場の分析と予測

第15章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 企業別市場シェア分析（2022年）
  • 企業プロファイル
    • Amgen, Inc.
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.
    • Heron Therapeutics, Inc.
    • Novartis AG
    • GSK plc
    • F. Hoffmann-La Roche Ltd.
    • Helsinn Healthcare SA
図表

List of Tables

  • Table 01: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 02: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 06: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 08: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 10: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 14: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 18: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 22: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Cancer Supportive Care Drugs Market Size (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Cancer Supportive Care Drugs Market Value Share, by Drug Class (2022)
  • Figure 03: Global Cancer Supportive Care Drugs Market Value Share, by Indication (2022)
  • Figure 04: Global Cancer Supportive Care Drugs Market Value Share, by Distribution Channel (2022)
  • Figure 05: Global Cancer Supportive Care Drugs Market Value Share, by Region (2022)
  • Figure 06: Global Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
  • Figure 07 Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
  • Figure 08: Global Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
  • Figure 09: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
  • Figure 10: Global Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
  • Figure 11: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 12: Global Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 13: Global Cancer Supportive Care Drugs Market Value Share, by Region, 2017-2031
  • Figure 14: Global Cancer Supportive Care Drugs Market Attractiveness Analysis, by Region, 2017-2031
  • Figure 15: North America Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
  • Figure 16: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
  • Figure 17: North America Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
  • Figure 18: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
  • Figure 19: North America Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
  • Figure 20: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 21: North America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 22: North America Cancer Supportive Care Drugs Market Value Share, by Country, 2017-2031
  • Figure 23: North America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 24: Europe Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
  • Figure 25: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
  • Figure 26: Europe Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
  • Figure 27: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
  • Figure 28: Europe Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
  • Figure 29: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 30: Europe Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 31: Europe Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 32: Europe Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 33: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
  • Figure 34: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
  • Figure 35: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
  • Figure 36: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
  • Figure 37: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
  • Figure 38: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 39: Asia Pacific Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 40: Asia Pacific Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 41: Asia Pacific Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 42: Latin America Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
  • Figure 43: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
  • Figure 44: Latin America Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
  • Figure 45: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
  • Figure 46: Latin America Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
  • Figure 47: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 48: Latin America Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 45: Latin America Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 50: Latin America Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 51: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Indication, 2022-2031
  • Figure 52: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Indication, 2017-2031
  • Figure 53: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Drug Class, 2022-2031
  • Figure 54: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Drug Class, 2017-2031
  • Figure 55: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Distribution Channel, 2022-2031
  • Figure 56: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 57: Middle East & Africa Cancer Supportive Care Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 58: Middle East & Africa Cancer Supportive Care Drugs Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 59: Middle East & Africa Cancer Supportive Care Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
目次
Product Code: TMRGL85941

Cancer Supportive Care Drugs Market - Scope of Report

TMR's report on the global cancer supportive care drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cancer supportive care drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer supportive care drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cancer supportive care drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cancer supportive care drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cancer supportive care drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cancer supportive care drugs market.

The report delves into the competitive landscape of the global cancer supportive care drugs market. Key players operating in the global cancer supportive care drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cancer supportive care drugs market profiled in this report.

Key Questions Answered in Global cancer supportive care drugs market Report:

  • What is the sales/revenue generated by wearable injectors across all regions during the forecast period?
  • What are the opportunities in the global cancer supportive care drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cancer Supportive Care Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global cancer supportive care drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cancer supportive care drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cancer supportive care drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Supportive Care Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Class Definition
    • 4.1.2. Industry Evolution/ Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
    • 4.4.2. Market Volume/Unit Shipments Projections
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Key Drug Class/Brand Analysis
  • 5.2. Top 3 Players Operating in the Market Space
  • 5.3. Disease Prevalence and Incidence
  • 5.4. COVID Impact Analysis

6. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Class, 2017-2031
    • 6.3.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
    • 6.3.2. ESAs (Erythropoiesis Stimulating Agent)
    • 6.3.3. Antiemetics
    • 6.3.4. Bisphosphonates
    • 6.3.5. Opioids
    • 6.3.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
    • 6.3.7. Others (Topicals, etc.)
  • 6.4. Market Attractiveness By Drug Class

7. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Indication, 2017-2031
    • 7.3.1. Lung Cancer
    • 7.3.2. Breast Cancer
    • 7.3.3. Prostate Cancer
    • 7.3.4. Liver Cancer
    • 7.3.5. Bladder Cancer
    • 7.3.6. Leukemia
    • 7.3.7. Others (Ovarian Cancer, Melanoma, etc.)
  • 7.4. Market Attractiveness By Indication

8. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others (Compounding Pharmacies, etc.)
  • 8.4. Market Attractiveness By Distribution Channel

9. Global Cancer Supportive Care Drugs Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Country/Region

10. North America Cancer Supportive Care Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Drug Class, 2017-2031
    • 10.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
    • 10.2.2. ESAs (Erythropoiesis Stimulating Agent)
    • 10.2.3. Antiemetics
    • 10.2.4. Bisphosphonates
    • 10.2.5. Opioids
    • 10.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
    • 10.2.7. Others (Topicals, etc.)
  • 10.3. Market Value Forecast By Indication, 2017-2031
    • 10.3.1. Lung Cancer
    • 10.3.2. Breast Cancer
    • 10.3.3. Prostate Cancer
    • 10.3.4. Liver Cancer
    • 10.3.5. Bladder Cancer
    • 10.3.6. Leukemia
    • 10.3.7. Others (Ovarian Cancer, Melanoma, etc.)
  • 10.4. Market Value Forecast By Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others (Compounding Pharmacies, etc.)
  • 10.5. Market Value Forecast By Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Cancer Supportive Care Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Class, 2017-2031
    • 11.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
    • 11.2.2. ESAs (Erythropoiesis Stimulating Agent)
    • 11.2.3. Antiemetics
    • 11.2.4. Bisphosphonates
    • 11.2.5. Opioids
    • 11.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
    • 11.2.7. Others (Topicals, etc.)
  • 11.3. Market Value Forecast By Indication, 2017-2031
    • 11.3.1. Lung Cancer
    • 11.3.2. Breast Cancer
    • 11.3.3. Prostate Cancer
    • 11.3.4. Liver Cancer
    • 11.3.5. Bladder Cancer
    • 11.3.6. Leukemia
    • 11.3.7. Others (Ovarian Cancer, Melanoma, etc.)
  • 11.4. Market Value Forecast By Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others (Compounding Pharmacies, etc.)
  • 11.5. Market Value Forecast By Country, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country

12. Asia Pacific Cancer Supportive Care Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Class, 2017-2031
    • 12.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
    • 12.2.2. ESAs (Erythropoiesis Stimulating Agent)
    • 12.2.3. Antiemetics
    • 12.2.4. Bisphosphonates
    • 12.2.5. Opioids
    • 12.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
    • 12.2.7. Others (Topicals, etc.)
  • 12.3. Market Value Forecast By Indication, 2017-2031
    • 12.3.1. Lung Cancer
    • 12.3.2. Breast Cancer
    • 12.3.3. Prostate Cancer
    • 12.3.4. Liver Cancer
    • 12.3.5. Bladder Cancer
    • 12.3.6. Leukemia
    • 12.3.7. Others (Ovarian Cancer, Melanoma, etc.)
  • 12.4. Market Value Forecast By Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others (Compounding Pharmacies, etc.)
  • 12.5. Market Value Forecast By Country, 2017-2031
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country

13. Latin America Cancer Supportive Care Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Class, 2017-2031
    • 13.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
    • 13.2.2. ESAs (Erythropoiesis Stimulating Agent)
    • 13.2.3. Antiemetics
    • 13.2.4. Bisphosphonates
    • 13.2.5. Opioids
    • 13.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
    • 13.2.7. Others (Topicals, etc.)
  • 13.3. Market Value Forecast By Indication, 2017-2031
    • 13.3.1. Lung Cancer
    • 13.3.2. Breast Cancer
    • 13.3.3. Prostate Cancer
    • 13.3.4. Liver Cancer
    • 13.3.5. Bladder Cancer
    • 13.3.6. Leukemia
    • 13.3.7. Others (Ovarian Cancer, Melanoma, etc.)
  • 13.4. Market Value Forecast By Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Others (Compounding Pharmacies, etc.)
  • 13.5. Market Value Forecast By Country, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country

14. Middle East & Africa Cancer Supportive Care Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Class, 2017-2031
    • 14.2.1. G-CSFs (Granulocyte Colony-Stimulating Factor)
    • 14.2.2. ESAs (Erythropoiesis Stimulating Agent)
    • 14.2.3. Antiemetics
    • 14.2.4. Bisphosphonates
    • 14.2.5. Opioids
    • 14.2.6. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
    • 14.2.7. Others (Topicals, etc.)
  • 14.3. Market Value Forecast By Indication, 2017-2031
    • 14.3.1. Lung Cancer
    • 14.3.2. Breast Cancer
    • 14.3.3. Prostate Cancer
    • 14.3.4. Liver Cancer
    • 14.3.5. Bladder Cancer
    • 14.3.6. Leukemia
    • 14.3.7. Others (Ovarian Cancer, Melanoma, etc.)
  • 14.4. Market Value Forecast By Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Others (Compounding Pharmacies, etc.)
  • 14.5. Market Value Forecast By Country, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Amgen, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Material Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Merck & Co., Inc.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Material Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Johnson & Johnson Services, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Material Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Heron Therapeutics, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Material Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Novartis AG
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Material Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. GSK plc
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Material Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F. Hoffmann-La Roche Ltd.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Material Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Helsinn Healthcare SA
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Material Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview